Get the Daily Brief
Latest Biotech News
Conference Week Drives Fresh Capital Into Biotech — Finance Report
BioCentury reported an uptick in biotech financing tied to JP Morgan Healthcare Conference week, with multiple new funds and financings announced, including activity from Arkin, Lux, a16z and...
AI‑Designed Antibodies Act as Live‑Cell Probes — Colorado State Team
Researchers at Colorado State University reported using artificial intelligence to redesign antibodies so they behave as fluorescent probes that reveal activity inside living cells, enabling...
ImmunityBio’s off‑the‑shelf CAR‑NK posts durable complete responses – Waldenström’s data
ImmunityBio disclosed early clinical results showing durable complete responses in patients with Waldenström’s macroglobulinemia treated with its allogeneic CD19 CAR‑NK cells plus rituximab. The...
ARPA‑H backs UC San Diego’s bid to 3D‑print patient livers – $25.8M award
UC San Diego received an ARPA‑H award — up to $25.77 million over 60 months — to develop patient‑specific, 3D‑bioprinted human livers under the PRINT program. The multidisciplinary project will...
AbbVie, Genmab’s Epkinly fails to extend overall survival in DLBCL – Phase 3 miss
AbbVie and Genmab announced that Epkinly (tucatinib? or Epkinly—company‑reported agent) did not prolong overall survival in a Phase 3 study for diffuse large B‑cell lymphoma (DLBCL). The...
Vedanta cuts headcount, pivots resources to VE303 phase 3 – layoffs to focus on C. difficile program
Vedanta Biosciences said it significantly reduced staff to concentrate remaining resources on its lead live‑biotherapeutic candidate VE303, now positioned for a Phase 3 study in recurrent...
NTU, Geneva identify E. faecalis redox mechanism that blocks wound healing – new therapeutic target
An international team led by Nanyang Technological University and the University of Geneva reported that Enterococcus faecalis impairs chronic wound healing by generating reactive oxygen species...
Foli Bio developing stool RNA‑seq panels to predict IBD response — noninvasive monitoring aim
Columbia University spinout Foli Bio is developing exfoliated fecal RNA sequencing panels intended to predict drug response in inflammatory bowel disease (IBD) patients and potentially replace...
GT Biopharma files IND for GTB‑5550 TriKE – NK engager targets B7‑H3 in solid tumors
GT Biopharma submitted an IND to the FDA for GTB‑5550, a TriKE (tri‑specific killer engager) targeting B7‑H3 for B7‑H3‑expressing solid tumors. The company plans a Phase 1 subcutaneous basket...
Bispecific antibody‑oligo conjugate offers neuron‑specific delivery…proof in vivo
Researchers at the University of Michigan presented preclinical data for a three‑part antibody‑oligonucleotide conjugate that ferries antisense oligonucleotides into neurons after crossing the...
FDA signals and process shifts: Phase‑1 rule tweaks and delayed voucher reviews
FDA leadership is signaling regulatory adjustments to speed early‑phase trials and respond to global competition, with Commissioner Marty Makary describing agency plans to rework Phase 1...
Big money heads to biotech: Novo Nordisk Foundation $850M pledge and JPM funding surge
The Novo Nordisk Foundation committed up to $850 million to scale Denmark’s BioInnovation Institute across Europe, expanding an innovation engine that has supported 131 startups to date. The move...
Epkinly misses overall survival in DLBCL — AbbVie, Genmab disclose
AbbVie and Genmab reported that Epkinly (tafasitamab-cxix) failed to prolong overall survival in a Phase 3 trial for diffuse large B‑cell lymphoma (DLBCL). The study enrolled patients who had...
UC San Diego wins $25.8M ARPA‑H award to 3D‑print patient livers
UC San Diego received up to $25,771,771 from ARPA‑H to develop a patient‑specific, fully functional 3D‑bioprinted liver under the PRINT program. The multidisciplinary effort, led by Shaochen Chen...
Off‑the‑shelf CAR‑NK yields durable CRs in Waldenström’s — ImmunityBio
Early Phase 1 data from ImmunityBio’s off‑the‑shelf allogeneic CD19 CAR‑NK therapy, given with rituximab, produced durable complete responses in four patients with Waldenström’s macroglobulinemia...
Enterococcus faecalis uses redox metabolism to stall wound healing — NTU‑led study
An international team led by Nanyang Technological University and the University of Geneva identified extracellular electron transport (EET) in Enterococcus faecalis as a mechanism that generates...
Two‑step genome editing creates full‑length humanized mice — new model
Researchers described a two‑step genome‑editing strategy that enables construction of full‑length humanized mouse models, overcoming limitations tied to divergent regulatory landscapes between...
Cells rewired as RNA recorders: new intracellular recording devices
A multidisciplinary team reported a platform that converts enigmatic intracellular structures into devices capable of recording RNA activity over time, providing an unbiased record of a cell’s...
Retrons drive synthetic DNA systems for protein targeting in cells
Researchers used bacterial retrons to build synthetic, non‑genetic DNA systems inside cells that bind specific proteins, creating programmable protein‑binding DNA constructs without altering the...
Foli Bio builds stool RNA panels to predict IBD drug response — Columbia spinout
Foli Bio, a Columbia University spinout, is developing stool‑based RNA‑seq panels from exfoliated fecal RNA to predict drug response in inflammatory bowel disease and reduce reliance on endoscopy...